Bristol-Myers Squibb Company's (BMY) Dividend Track Record: A Must-Have for a Dividend Stock Portfolio

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Stock Portfolio.

Bristol-Myers Squibb Company (NYSE:BMY) is a pharmaceutical company focused on developing treatments across cancer, blood disorders, cardiovascular disease, immunology, and neuroscience. Its portfolio includes widely recognized therapies such as Opdivo for oncology and Eliquis for preventing blood clots, alongside a growing pipeline in cell therapy and immunology.

In recent years, Bristol-Myers Squibb Company (NYSE:BMY) has concentrated on expanding its “Growth Portfolio” by launching new medicines and strengthening its global presence, while also adding assets through acquisitions and partnerships. A major challenge lies in balancing this growth with revenue declines from its “Legacy Portfolio,” as older drugs lose patent protection and face generic competition. To address this, Bristol Myers Squibb continues to prioritize research and development, build strategic collaborations, and navigate regulatory and pricing pressures across international markets.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks for a dividend stock portfolio, as the company has grown its payouts for 16 consecutive years. On September 17, the company declared a quarterly dividend of $0.62 per share, which was in line with its previous dividend. The stock supports a dividend yield of 5.42%, as of September 18.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Consistent Dividend Stocks to Buy Now and 15 Best Performing Dividend Stocks So Far in 2025.

Disclosure: None.